# A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

> **NCT06981858** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Chongqing University Cancer Hospital** · enrollment: 34 (estimated)

## Conditions studied

- LOCALLY ADVANCED CERVICAL CANCERS

## Interventions

- **DRUG:** Enlonstobart Injection

## Key facts

- **NCT ID:** NCT06981858
- **Lead sponsor:** Chongqing University Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-15
- **Primary completion:** 2029-02-01
- **Final completion:** 2029-02-01
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06981858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06981858, "A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06981858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*